Literature DB >> 21048526

Doxorubicin pathways: pharmacodynamics and adverse effects.

Caroline F Thorn1, Connie Oshiro, Sharon Marsh, Tina Hernandez-Boussard, Howard McLeod, Teri E Klein, Russ B Altman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21048526      PMCID： PMC3116111          DOI： 10.1097/FPC.0b013e32833ffb56

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  61 in total

Review 1.  Different anthracycline derivates for reducing cardiotoxicity in cancer patients.

Authors:  Elvira C van Dalen; Erna Mc Michiels; Huib N Caron; Leontien Cm Kremer
Journal:  Cochrane Database Syst Rev       Date:  2010-05-12

Review 2.  Pharmacogenetics of target genes across doxorubicin disposition pathway: a review.

Authors:  Suman Lal; Anupama Mahajan; Wei Ning Chen; Balram Chowbay
Journal:  Curr Drug Metab       Date:  2010-01       Impact factor: 3.731

3.  Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism.

Authors:  Onkar S Bains; Morgan J Karkling; Joanna M Lubieniecka; Thomas A Grigliatti; Ronald E Reid; K Wayne Riggs
Journal:  J Pharmacol Exp Ther       Date:  2009-12-09       Impact factor: 4.030

Review 4.  New developments in anthracycline-induced cardiotoxicity.

Authors:  A Mordente; E Meucci; A Silvestrini; G E Martorana; B Giardina
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

5.  Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer.

Authors:  Sharad S Singhal; Archana Sehrawat; Mukesh Sahu; Preeti Singhal; Rit Vatsyayan; Poorna Chandra Rao Lelsani; Sushma Yadav; Sanjay Awasthi
Journal:  Int J Cancer       Date:  2010-03-15       Impact factor: 7.396

6.  Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood.

Authors:  Vladan Rajić; Richard Aplenc; Marusa Debeljak; Veronika Velensek Prestor; Natasa Karas-Kuzelicki; Irena Mlinaric-Rascan; Janez Jazbec
Journal:  Leuk Lymphoma       Date:  2009-10

Review 7.  The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.

Authors:  Catherine Oakman; Erica Moretti; Francesca Galardi; Libero Santarpia; Angelo Di Leo
Journal:  Cancer Treat Rev       Date:  2009-09-15       Impact factor: 12.111

8.  Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.

Authors:  Ji-Yeob Choi; William E Barlow; Kathy S Albain; Chi-Chen Hong; Javier G Blanco; Robert B Livingston; Warren Davis; James M Rae; I-Tien Yeh; Laura F Hutchins; Peter M Ravdin; Silvana Martino; Alan P Lyss; C Kent Osborne; Martin D Abeloff; Daniel F Hayes; Christine B Ambrosone
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

9.  Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol.

Authors:  R D Olson; P S Mushlin; D E Brenner; S Fleischer; B J Cusack; B K Chang; R J Boucek
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

Review 10.  Doxorubicin: the good, the bad and the ugly effect.

Authors:  Cristina Carvalho; Renato X Santos; Susana Cardoso; Sónia Correia; Paulo J Oliveira; Maria S Santos; Paula I Moreira
Journal:  Curr Med Chem       Date:  2009-09-01       Impact factor: 4.530
View more
  317 in total

1.  Multiphoton fluorescence lifetime imaging of chemotherapy distribution in solid tumors.

Authors:  Marjorie Carlson; Adrienne L Watson; Leah Anderson; David A Largaespada; Paolo P Provenzano
Journal:  J Biomed Opt       Date:  2017-11       Impact factor: 3.170

2.  Embryonic stem cell-derived exosomes inhibit doxorubicin-induced TLR4-NLRP3-mediated cell death-pyroptosis.

Authors:  Zahra Tavakoli Dargani; Dinender K Singla
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-06-07       Impact factor: 4.733

3.  Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells.

Authors:  Oana Tudoran; Olga Soritau; Loredana Balacescu; Simona Visan; Otilia Barbos; Roxana Cojocneanu-Petric; Ovidiu Balacescu; Ioana Berindan-Neagoe
Journal:  Mol Cell Biochem       Date:  2015-07-18       Impact factor: 3.396

Review 4.  Conditioning neoadjuvant therapies for improved immunotherapy of cancer.

Authors:  Zachary Benson; Saeed H Manjili; Mehran Habibi; Georgi Guruli; Amir A Toor; Kyle K Payne; Masoud H Manjili
Journal:  Biochem Pharmacol       Date:  2017-08-10       Impact factor: 5.858

5.  Exercise stimulates beneficial adaptations to diminish doxorubicin-induced cellular toxicity.

Authors:  Ashley J Smuder
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-08-28       Impact factor: 3.619

Review 6.  Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment.

Authors:  David Howard; Jetzabel Garcia-Parra; Gareth D Healey; Cynthia Amakiri; Lavinia Margarit; Lewis W Francis; Deyarina Gonzalez; R Steven Conlan
Journal:  Interface Focus       Date:  2016-12-06       Impact factor: 3.906

7.  Chemotherapeutic drug-specific alteration of microvascular blood flow in murine breast cancer as measured by diffuse correlation spectroscopy.

Authors:  Gabriel Ramirez; Ashley R Proctor; Ki Won Jung; Tong Tong Wu; Songfeng Han; Russell R Adams; Jingxuan Ren; Daniel K Byun; Kelley S Madden; Edward B Brown; Thomas H Foster; Parisa Farzam; Turgut Durduran; Regine Choe
Journal:  Biomed Opt Express       Date:  2016-08-24       Impact factor: 3.732

8.  Hepatocellular carcinoma cells surviving doxorubicin treatment exhibit increased migratory potential and resistance to doxorubicin re-treatment in vitro.

Authors:  Sebastian Buschauer; Andreas Koch; Philipp Wiggermann; Martina Müller; Claus Hellerbrand
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

9.  R-CHOEP14 in younger high-risk patients with large B cell lymphoma: an effective front-line regimen with cardiac toxicity: a real-life, single-center experience.

Authors:  Sandra Bašić-Kinda; Ivo Radman; Dino Dujmović; Ivana Ilić; Marko Kralik; Margareta Dobrenić; Lea Galunić-Bilić; Pavle Rončević; Marijo Vodanović; Zrinka Sertić; Ida Hude; Igor Aurer
Journal:  Ann Hematol       Date:  2020-11-20       Impact factor: 3.673

10.  Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma.

Authors:  Jonás Samuel Pérez-Blanco; Dolores Santos-Buelga; María Del Mar Fernández de Gatta; Jesús María Hernández-Rivas; Alejandro Martín; María José García
Journal:  Br J Clin Pharmacol       Date:  2016-09-06       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.